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In the developed world there has been a substantial increase over several decades in the 
prevalence of congestive heart failure (CHF), partly as a result of demographic changes. 
Overall, 1-2% of the adult population has CHF and this increases to ≥10% in the over 70’s (1). 
However, hospitalisation rates due to CHF are falling (2) and length of hospital stay and in-
hospital mortality have also fallen (3). It could be argued that effective outpatient management 
of CHF through dedicated heart failure clinics, specialist nurses and general practitioners has 
played a key role in these positive trends.   
However, given the significant patient morbidity and the inpatient costs associated with CHF, 
methods to reduce hospital readmission rates are imperative to alleviate an already over-
stretched system. In this edition of the journal, Rahimi and Colleagues present the 
development and assessment of an easy-to-use, Android-based monitoring system to 
empower patients and reduce readmission rates in a cohort from the Seamless User-centred 
Proactive Provision Of Risk-stratified Treatment for Heart Failure (SUPPORT-HF) study. 
Patients were provided with Internet-enabled tablets which were connected to commercially 
available sensors to record blood pressure, heart rate and weight, and provide alerts to 
patients to see their doctor or health provider when physiological parameters were perturbed. 
Although this particular self-management study focused primarily on patient uptake of 
monitoring systems and did not offer any medical interventions beyond patient alerts to seek 
medical advice, the device was well received by patients and impressively, was reported as 
‘easy-to-use’ in a cohort with a median age of 77 years and relatively little experience with 
digital systems. The tablets also provided access to educational materials for patients to view, 
including video clips about CHF and its management. This study presents an elegant yet 
simple method for patient monitoring and the findings indicate an underlying desire of patients 
to be involved in their own medical care.  
Several forms of telemonitoring have been employed in CHF; remote patient telephone 
support, external monitoring devices, specialised implantable haemodynamic monitoring 
devices, and pre-existing device adaptation technologies. In a systematic review, Inglis et al. 
(2010) noted a reduction in risk of mortality and hospitalisation from CHF with the use of 
telemonitoring. Furthermore, a more recent meta-analysis by Pandor et al. (2013) showed a 
reduction in mortality in studies that used telemonitoring data to provide 24/7 patient support. 
However critics point out that many of these studies had unblinded analysts, few participants, 
and only a moderate standard of methodological quality (4). More recently, the Patient-
Centred Disease Management (PCDM) for Heart Failure trial (2015) also failed to demonstrate 
a significant difference in health status with telemonitoring in heart failure patients.  
Comparison of telemonitoring studies is complicated by the heterogeneity in the degree of 
contact with patients, and the ability to ‘close the loop’ between detection of perturbations in 
physiological parameters, notification of healthcare professionals, treatment, and assessment 
of treatment outcomes (4, 5). Most studies assessing treatments initiated in response to 
telemonitoring data have involved alterations in the doses of oral diuretics and organic nitrates; 
the feasibility of outpatient intravenous diuretic therapy is an avenue that requires further 
exploration. 
New generation pacing and defibrillator systems are capable of measuring, storing and 
remotely transmitting heart rate, activity-level and intrathoracic impedance data. Decreased 
heart rate variability indicates autonomic imbalance with decreased cardiac vagal tone and 
increased sympathetic tone, and predicts CHF related hospitalisations days to weeks prior (6). 
A fall in patient activity levels might also give a clue to disease progression and may serve as 
a valuable educational tool for patients and their families to stress the importance of physical 
activity (7). A reduction in baseline intrathoracic impedance can identify increased fluid 
retention and increased LA filling (wedge) pressure, thus indicating possible decompensating 
CHF. Intrathoracic impedance devices may be limited however, by fluid accumulation within 
the path of the measurement area (such as oedema, inflammation or haematoma within the 
device pocket) or by intrathoracic processes such as pleural effusions or pneumonia (8). 
Intrathoracic impedance was shown to be superior to daily weight monitoring and predicts 
CHF decompensation 10-14 days in advance (9). The benefit of these potential advantages, 
however, has been inconsistently demonstrated in randomised trials (10, 11). Daily device-
based monitoring for tachyarrhythmias, increased intrathoracic impedance and reduced 
physical activity in the recent randomised, multi-centre IN-TIME trial (2014) in patients with 
implanted defibrillators, encouragingly showed a positive trend in mortality and hospital 
admissions in device-monitored patients. Developments in impedance cardiography (ICG), 
which allows for non-invasive measurement of intrathoracic impedance, have also shown 
positive results (12), however the data are not significant enough to supplant invasive 
measurements. Future research could explore these gaps in the evidence base. 
Specialised implantable hemodynamic monitors (IHM) can measure right 
ventricular/estimated pulmonary artery pressure along with heart rate, temperature and 
activity level and are another exciting prospect. Initial studies have established safety of the 
devices and the results are encouraging. In the CHAMPION trial (2014), 550 patients with 
NYHA class III symptoms and a prior hospitalisation for CHF received a wireless implantable 
pulmonary artery pressure sensor and were randomised to treatment with or without the 
assistance of sensor data. At 6 months, there was a 30% reduction in the primary end-point 
of CHF hospitalisations (HR 0.70, 95%CI, 0.60–0.84, P=0.0001). These data suggest that for 
selected patients with advanced CHF symptoms, continuous monitoring of intra-cardiac 
pressures may provide a reliable signal both for early detection of deterioration and for tracking 
effectiveness of early intervention that can facilitate improvements in clinical outcomes. 
Potentially, such additional data could help risk-stratify heart failure patients at high risk of 
sudden cardiac death. 
Conclusion:  
This study by Rahimi and Colleagues, assessing telemonitoring technologies in a cohort of 
patients from SUPPORT-HF, demonstrates an easy-to-use technological home-monitoring 
system that was well accepted by heart failure patients. Despite the fact that the verdict on 
previous telemonitoring technologies is still out, there are signs that this technology is 
improving rapidly and it looks like they will have a significant role in the optimal management 
of patients with CHF in the future. It is likely that the greatest promise lies with next-generation 
home monitoring systems, provided strategies are implemented for integrating them 
effectively into the healthcare framework to close the loop between patients and healthcare 
providers.   
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